- Home
- HMY vs LNTH Comparison
HMY vs LNTH Comparison
Compare HMY & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HMY | LNTH |
|---|---|---|
| Founded | 1950 | 1956 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 4.4B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | HMY | LNTH |
|---|---|---|
| Price | $21.72 | $66.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $16.00 | ★ $78.00 |
| AVG Volume (30 Days) | ★ 3.9M | 1.2M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 67.74 | N/A |
| EPS | 1.29 | ★ 2.39 |
| Revenue | ★ $4,161,584,110.00 | $1,525,933,000.00 |
| Revenue This Year | $40.10 | $0.01 |
| Revenue Next Year | $14.83 | $0.52 |
| P/E Ratio | ★ $16.74 | $27.87 |
| Revenue Growth | ★ 20.39 | 1.95 |
| 52 Week Low | $7.97 | $47.25 |
| 52 Week High | $22.25 | $111.29 |
Technical Indicators
Market Signals| Indicator | HMY | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 65.42 |
| Support Level | $21.22 | $64.13 |
| Resistance Level | $21.96 | $68.84 |
| Average True Range (ATR) | 0.78 | 1.91 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 92.89 | 75.07 |
Price Performance
Historical ComparisonAbout HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.